Marianna Janion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marianna Janion has a total of 925 co-authors. Here are the top co-authors by number of shared publications:
- Anna Polewczyk
Department of Physiology, Pathophysiology and Clinical Immunology Collegium Medicum of Jan Kochanowski University Kielce Poland
35 shared publications - Marcin Sadowski
Faculty of Medicine, Jan Kochanowski University in Kielce, al. IX Wieków Kielc 19a, 25-516 Kielce, Poland
27 shared publications - Jacek Kurzawski
Faculty of Medicine, Jan Kochanowski University in Kielce, al. IX Wieków Kielc 19a, 25-516 Kielce, Poland
20 shared publications Agnieszka Janion-Sadowska
Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
19 shared publications- Janusz Sielski
Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
19 shared publications - Marek Gierlotka
Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland
15 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8552
Left Atrial Appendage Thrombus and Long-Term Clinical Outcomes in Anticoagulated Patients with Atrial Fibrillation and Atrial Flutter Referred for a Rhythm-Control Strategy: A Prospective Observational Cohort Study
Background/Objectives: Whether long-term prognosis differs between patients with atrial fibrillation (AF) and those with atrial flutter (AFL) after adjustment for baseline cardiovascular characteristics remains unclear. Methods: In this prospective observational cohort study, we enrolled 656 patients meeting predefined anticoagulation eligibility criteria with AF (n = 558) or AFL (n = 98) who underwent transesophageal echocardiography (TEE) before a planned rhythm-control intervention. The primary endpoint was left atrial appendage thrombus (LAAT) detected at the index TEE. Long-term outcomes included cardiovascular death, heart failure (HF) hospitalization, ischemic stroke, transient ischemic attack, myocardial infarction, and systemic thromboembolism. Results: LAAT was detected in 14.2% of patients with AF and 10.2% of patients with AFL (p = 0.29). After multivariable adjustment, AFL versus AF was not independently associated with LAAT (adjusted odds ratio [aOR], 0.53; 95% confidence interval [CI], 0.25–1.11; p = 0.09). Median follow-up was 6.85 (3.64–8.53) years. Cardiovascular death occurred in 96 patients (14.6%; AF: n = 78, AFL: n = 18), and HF hospitalization occurred in 91 patients (13.9%; AF: n = 78, AFL: n = 13). Log-rank comparisons were not statistically significant for cardiovascular death (log-rank p = 0.42) or HF hospitalization (log-rank p = 0.73). In extended Cox models that accounted for nonproportional hazards, AFL versus AF was not independently associated with cardiovascular death (adjusted hazard ratio [aHR], 1.09; 95% CI, 0.64–1.85; p = 0.75) or HF hospitalization (aHR, 0.69; 95% CI, 0.37–1.27; p = 0.23). Conclusions: Catheter ablation was recorded in 83.7% of AFL versus 24.6% of AF patients, including index-hospitalization ablation in 46.9% versus 0%, respectively. In this selected cohort meeting predefined anticoagulation eligibility criteria referred for TEE-guided rhythm control, no statistically significant independent association was detected between index arrhythmia type (AF versus AFL) and LAAT, cardiovascular death, or HF hospitalization. Importantly, these findings describe associations under markedly different subsequent rhythm-control treatment pathways and do not establish equivalent intrinsic risks for AF and AFL. The smaller AFL group (n = 98) and wide confidence intervals limit precision; clinically meaningful differences cannot be excluded. These findings should not be extrapolated to unselected AF/AFL populations, including asymptomatic patients, those managed exclusively with rate control, or patients not receiving anticoagulation. The comparison is based on presenting arrhythmia, not a rhythm phenotype confirmed to persist throughout follow-up; incident AF among patients initially presenting with AFL was not systematically ascertained.
- 3 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8552
Open AccessLeft Atrial Appendage Thrombus and Long-Term Clinical Outcomes in Anticoagulated Patients with Atrial Fibrillation and Atrial Flutter Referred for a Rhythm-Control Strategy: A Prospective Observational Cohort Study
Background/Objectives: Whether long-term prognosis differs between patients with atrial fibrillation (AF) and those with atrial flutter (AFL) after adjustment for baseline cardiovascular characteristics remains unclear. Methods: In this prospective observational cohort study, we enrolled 656 patients meeting predefined anticoagulation eligibility criteria with AF (n = 558) or AFL (n = 98) who underwent transesophageal echocardiography (TEE) before a planned rhythm-control intervention. The primary endpoint was left atrial appendage thrombus (LAAT) detected at the index TEE. Long-term outcomes included cardiovascular death, heart failure (HF) hospitalization, ischemic stroke, transient ischemic attack, myocardial infarction, and systemic thromboembolism. Results: LAAT was detected in 14.2% of patients with AF and 10.2% of patients with AFL (p = 0.29). After multivariable adjustment, AFL versus AF was not independently associated with LAAT (adjusted odds ratio [aOR], 0.53; 95% confidence interval [CI], 0.25–1.11; p = 0.09). Median follow-up was 6.85 (3.64–8.53) years. Cardiovascular death occurred in 96 patients (14.6%; AF: n = 78, AFL: n = 18), and HF hospitalization occurred in 91 patients (13.9%; AF: n = 78, AFL: n = 13). Log-rank comparisons were not statistically significant for cardiovascular death (log-rank p = 0.42) or HF hospitalization (log-rank p = 0.73). In extended Cox models that accounted for nonproportional hazards, AFL versus AF was not independently associated with cardiovascular death (adjusted hazard ratio [aHR], 1.09; 95% CI, 0.64–1.85; p = 0.75) or HF hospitalization (aHR, 0.69; 95% CI, 0.37–1.27; p = 0.23). Conclusions: Catheter ablation was recorded in 83.7% of AFL versus 24.6% of AF patients, including index-hospitalization ablation in 46.9% versus 0%, respectively. In this selected cohort meeting predefined anticoagulation eligibility criteria referred for TEE-guided rhythm control, no statistically significant independent association was detected between index arrhythmia type (AF versus AFL) and LAAT, cardiovascular death, or HF hospitalization. Importantly, these findings describe associations under markedly different subsequent rhythm-control treatment pathways and do not establish equivalent intrinsic risks for AF and AFL. The smaller AFL group (n = 98) and wide confidence intervals limit precision; clinically meaningful differences cannot be excluded. These findings should not be extrapolated to unselected AF/AFL populations, including asymptomatic patients, those managed exclusively with rate control, or patients not receiving anticoagulation. The comparison is based on presenting arrhythmia, not a rhythm phenotype confirmed to persist throughout follow-up; incident AF among patients initially presenting with AFL was not systematically ascertained.
- Open Access
- 26 December 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e949758
Isolated Neck Pain as an Atypical Manifestation of Type A Acute Aortic Dissection: A Case Report
BACKGROUND Acute aortic dissection (AAD) is a life-threatening cardiovascular emergency that is most commonly associated with severe chest or back pain. Atypical symptoms such as isolated neck pain may lead to delayed diagnosis and treatment, increasing the risk of mortality. In this report, we present a diagnostically challenging case of AAD with atypical symptoms in order to increase clinical awareness and support earlier recognition of such presentations. CASE REPORT A 30-year-old man with obesity, a 10-pack-year smoking history, arterial hypertension, and a family history of AAD presented with isolated neck pain and a transient presyncopal episode following mild exertion. Laboratory tests showed leukocytosis and elevated D-dimer, troponin, and NT-proBNP levels. Transthoracic echocardiography raised suspicion of Type A AAD, although the initial contrast-enhanced computed tomography (CT) scan did not confirm the diagnosis. Due to continued clinical concerns, CT scan was repeated, and it revealed a Stanford Type A dissection. The patient underwent emergency surgery involving the resection of the affected segment of the ascending aorta and graft replacement using a synthetic prosthesis. His postoperative course was uneventful, and he remained asymptomatic at follow-up. CONCLUSIONS This case report highlights isolated neck pain as an atypical but potentially critical presentation of Type A AAD. Early recognition of atypical features in high-risk patients is essential. Multimodal imaging is crucial for timely diagnosis and improved survival outcomes.
- 26 December 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e949758
Open AccessIsolated Neck Pain as an Atypical Manifestation of Type A Acute Aortic Dissection: A Case Report
BACKGROUND Acute aortic dissection (AAD) is a life-threatening cardiovascular emergency that is most commonly associated with severe chest or back pain. Atypical symptoms such as isolated neck pain may lead to delayed diagnosis and treatment, increasing the risk of mortality. In this report, we present a diagnostically challenging case of AAD with atypical symptoms in order to increase clinical awareness and support earlier recognition of such presentations. CASE REPORT A 30-year-old man with obesity, a 10-pack-year smoking history, arterial hypertension, and a family history of AAD presented with isolated neck pain and a transient presyncopal episode following mild exertion. Laboratory tests showed leukocytosis and elevated D-dimer, troponin, and NT-proBNP levels. Transthoracic echocardiography raised suspicion of Type A AAD, although the initial contrast-enhanced computed tomography (CT) scan did not confirm the diagnosis. Due to continued clinical concerns, CT scan was repeated, and it revealed a Stanford Type A dissection. The patient underwent emergency surgery involving the resection of the affected segment of the ascending aorta and graft replacement using a synthetic prosthesis. His postoperative course was uneventful, and he remained asymptomatic at follow-up. CONCLUSIONS This case report highlights isolated neck pain as an atypical but potentially critical presentation of Type A AAD. Early recognition of atypical features in high-risk patients is essential. Multimodal imaging is crucial for timely diagnosis and improved survival outcomes.
- Open Access
- 18 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7724
Cardiovascular Outcomes in Patients with Atrial Flutter and Oral Anticoagulation: The Predictive Role of Left Atrial Appendage Thrombus in a Long-Term, Prospective, Observational Cohort Study
Background/Objectives: The risks of blood clot formation, stroke, heart failure (HF), and cardiovascular death are enhanced in individuals with atrial flutter (AFL). However, it remains unclear whether left atrial appendage thrombus (LAAT) in individuals with AFL with anticoagulation enhances the risk of cardiovascular morbidity and mortality. Thus, in the current trial, we aimed to evaluate the predictive role of LAAT for cardiovascular outcomes in individuals with AFL who were receiving anticoagulation and admitted for electrical cardioversion. Methods: Ninety patients were included in this prospective observational cohort study. The primary endpoint was the identification of LAAT by transesophageal echocardiographic examination. All participants were observed for a median of 2114.5 (interquartile range, 1487.5–2591) days to identify the secondary endpoints: cardiovascular death, transient ischemic attack (TIA), stroke, systemic thromboembolic complications, hospitalization due to HF, or myocardial infarction. Results: LAAT was identified in nine (10%) patients. No differences in cardiovascular outcomes between patients with and without LAAT were documented. However, a higher CHA2DS2-VASc score, previous myocardial infarction, and previous stroke/TIA/systemic thromboembolism were associated with significantly higher rates of hospitalization due to HF. Decreased left ventricular ejection fraction (LVEF) was associated with significantly higher rates of cardiovascular death, underscoring the significance of this marker in disease prognosis. Conclusions: The impact of LAAT on cardiovascular outcomes was insignificant. Higher CHA2DS2-VASc scores, previous myocardial infarction, previous stroke/TIA/systemic thromboembolism, and lower LVEF significantly affected long-term prognosis and were associated with a poor prognosis.
- 18 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7724
Open AccessCardiovascular Outcomes in Patients with Atrial Flutter and Oral Anticoagulation: The Predictive Role of Left Atrial Appendage Thrombus in a Long-Term, Prospective, Observational Cohort Study
Background/Objectives: The risks of blood clot formation, stroke, heart failure (HF), and cardiovascular death are enhanced in individuals with atrial flutter (AFL). However, it remains unclear whether left atrial appendage thrombus (LAAT) in individuals with AFL with anticoagulation enhances the risk of cardiovascular morbidity and mortality. Thus, in the current trial, we aimed to evaluate the predictive role of LAAT for cardiovascular outcomes in individuals with AFL who were receiving anticoagulation and admitted for electrical cardioversion. Methods: Ninety patients were included in this prospective observational cohort study. The primary endpoint was the identification of LAAT by transesophageal echocardiographic examination. All participants were observed for a median of 2114.5 (interquartile range, 1487.5–2591) days to identify the secondary endpoints: cardiovascular death, transient ischemic attack (TIA), stroke, systemic thromboembolic complications, hospitalization due to HF, or myocardial infarction. Results: LAAT was identified in nine (10%) patients. No differences in cardiovascular outcomes between patients with and without LAAT were documented. However, a higher CHA2DS2-VASc score, previous myocardial infarction, and previous stroke/TIA/systemic thromboembolism were associated with significantly higher rates of hospitalization due to HF. Decreased left ventricular ejection fraction (LVEF) was associated with significantly higher rates of cardiovascular death, underscoring the significance of this marker in disease prognosis. Conclusions: The impact of LAAT on cardiovascular outcomes was insignificant. Higher CHA2DS2-VASc scores, previous myocardial infarction, previous stroke/TIA/systemic thromboembolism, and lower LVEF significantly affected long-term prognosis and were associated with a poor prognosis.
- Open Access
- 5 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5258
Left Atrial Appendage Thrombus as a Marker of Disease Severity in 500 Patients with Atrial Fibrillation on Oral Anticoagulation: A 13-Year Follow-Up Study
Background/Objective: Whether left atrial appendage thrombus (LAAT) in patients with atrial fibrillation (AF) on chronic anticoagulation significantly increases cardiovascular risk is unknown. This study aimed to assess LAAT prevalence and its predictive role in cardiovascular events among consecutive anticoagulated patients with AF admitted for electrical cardioversion. Methods: This prospective study included 500 patients. The primary outcome was LAAT on transesophageal echocardiography. Patients were followed up for a median of 1927.5 (interquartile range 1004–2643) days to assess cardiovascular events. Results: LAAT was detected in 65 (13%) patients. No significant differences in stroke, transient ischemic attack, systemic thromboembolic events, or myocardial infarction prevalence were observed between patients with AF with and without LAAT. Hospitalization for heart failure (HF) was more frequent in patients with LAAT than in those without LAAT; however, the effect of LAAT on HF hospitalization was not statistically significant. Patients with LAAT had a significantly higher risk of cardiovascular death than those without LAAT. LAAT and greater left atrial (LA) diameter were associated with higher rates of cardiovascular death. The independent HF hospitalization predictors were greater LA diameter, lower left ventricular ejection fraction (LVEF), and estimated glomerular filtration rate (eGFR). Conclusions: Patients with AF who received anticoagulation therapy showed a high prevalence of LAAT. LAAT and greater LA diameter were associated with significantly higher rates of cardiovascular death. LAAT, greater LA diameter, lower LVEF, and lower eGFR were associated with poor prognosis in anticoagulated patients with AF and were predictors of disease severity.
- 5 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5258
Open AccessLeft Atrial Appendage Thrombus as a Marker of Disease Severity in 500 Patients with Atrial Fibrillation on Oral Anticoagulation: A 13-Year Follow-Up Study
Background/Objective: Whether left atrial appendage thrombus (LAAT) in patients with atrial fibrillation (AF) on chronic anticoagulation significantly increases cardiovascular risk is unknown. This study aimed to assess LAAT prevalence and its predictive role in cardiovascular events among consecutive anticoagulated patients with AF admitted for electrical cardioversion. Methods: This prospective study included 500 patients. The primary outcome was LAAT on transesophageal echocardiography. Patients were followed up for a median of 1927.5 (interquartile range 1004–2643) days to assess cardiovascular events. Results: LAAT was detected in 65 (13%) patients. No significant differences in stroke, transient ischemic attack, systemic thromboembolic events, or myocardial infarction prevalence were observed between patients with AF with and without LAAT. Hospitalization for heart failure (HF) was more frequent in patients with LAAT than in those without LAAT; however, the effect of LAAT on HF hospitalization was not statistically significant. Patients with LAAT had a significantly higher risk of cardiovascular death than those without LAAT. LAAT and greater left atrial (LA) diameter were associated with higher rates of cardiovascular death. The independent HF hospitalization predictors were greater LA diameter, lower left ventricular ejection fraction (LVEF), and estimated glomerular filtration rate (eGFR). Conclusions: Patients with AF who received anticoagulation therapy showed a high prevalence of LAAT. LAAT and greater LA diameter were associated with significantly higher rates of cardiovascular death. LAAT, greater LA diameter, lower LVEF, and lower eGFR were associated with poor prognosis in anticoagulated patients with AF and were predictors of disease severity.
- Open Access
- 4 July 2022
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 29 (4) , 540-552
Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
- 4 July 2022
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 29 (4) , 540-552
Open AccessPre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
- Open Access
- 21 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3377
Myocardial Infarction in Centenarians. Data from The Polish Registry of Acute Coronary Syndromes
Background: There are no data regarding the mortality rate, risks and benefits of particular reperfusion methods and pharmacological treatment complications in patients aged over 100 years with acute coronary syndromes. We sought to assess the treatment of myocardial infarction (MI) in patients older than 100 years and to determine prognostic factors for this group. Methods: Among the 716,566 patients recorded between 2003 and 2018 in the Polish Registry of Acute Coronary Syndromes, 104 patients aged ≥100 with MI were included. The patients were categorized into two groups: group 1 received conservative treatment (64 patients), and group 2 received invasive strategy (40 patients). Results: The frequencies of in-hospital mortality, MI and stroke were similar in both arms. No difference in the frequency of the combined endpoint (death, reinfarction, stroke) was noted. Invasive treatment was more advantageous for 12-month outcomes; 50 patients in group 1 (79%) and 23 patients in group 2 (57.50%) died (p = 0.017). The multivariate analysis identified the lower left ventricular ejection fraction (EF) (Hazard Ratio (HR) = 0.96; 95% Confidence Interval (CI): 0.94–0.99; p = 0.012), lack of coronary angiography (HR = 0.49; 95% CI: 0.24–0.99; p = 0.048) and cardiac arrest (HR = 4.61; 95% CI: 1.64–12.99; p = 0.0038) as predictors of 12-month mortality in this group. Conclusions: Invasive MI treatment may be beneficial for selected very old patients.
- 21 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3377
Open AccessMyocardial Infarction in Centenarians. Data from The Polish Registry of Acute Coronary Syndromes
Background: There are no data regarding the mortality rate, risks and benefits of particular reperfusion methods and pharmacological treatment complications in patients aged over 100 years with acute coronary syndromes. We sought to assess the treatment of myocardial infarction (MI) in patients older than 100 years and to determine prognostic factors for this group. Methods: Among the 716,566 patients recorded between 2003 and 2018 in the Polish Registry of Acute Coronary Syndromes, 104 patients aged ≥100 with MI were included. The patients were categorized into two groups: group 1 received conservative treatment (64 patients), and group 2 received invasive strategy (40 patients). Results: The frequencies of in-hospital mortality, MI and stroke were similar in both arms. No difference in the frequency of the combined endpoint (death, reinfarction, stroke) was noted. Invasive treatment was more advantageous for 12-month outcomes; 50 patients in group 1 (79%) and 23 patients in group 2 (57.50%) died (p = 0.017). The multivariate analysis identified the lower left ventricular ejection fraction (EF) (Hazard Ratio (HR) = 0.96; 95% Confidence Interval (CI): 0.94–0.99; p = 0.012), lack of coronary angiography (HR = 0.49; 95% CI: 0.24–0.99; p = 0.048) and cardiac arrest (HR = 4.61; 95% CI: 1.64–12.99; p = 0.0038) as predictors of 12-month mortality in this group. Conclusions: Invasive MI treatment may be beneficial for selected very old patients.
- Open Access
- 2 January 2020
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 18 (1) , 1-18
Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications
Nanotechnology-based therapeutic approaches have attracted attention of scientists, in particular due to the special features of nanomaterials, such as adequate biocompatibility, ability to improve therapeutic efficiency of incorporated drugs and to limit their adverse effects. Among a variety of reported nanomaterials for biomedical applications, metal and metal oxide-based nanoparticles offer unique physicochemical properties allowing their use in combination with conventional antimicrobials and as magnetic field-controlled drug delivery nanocarriers. An ever-growing number of studies demonstrate that by combining magnetic nanoparticles with membrane-active, natural human cathelicidin-derived LL-37 peptide, and its synthetic mimics such as ceragenins, innovative nanoagents might be developed. Between others, they demonstrate high clinical potential as antimicrobial, anti-cancer, immunomodulatory and regenerative agents. Due to continuous research, knowledge on pleiotropic character of natural antibacterial peptides and their mimics is growing, and it is justifying to stay that the therapeutic potential of nanosystems containing membrane active compounds has not been exhausted yet.
- 2 January 2020
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 18 (1) , 1-18
Open AccessNanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications
Nanotechnology-based therapeutic approaches have attracted attention of scientists, in particular due to the special features of nanomaterials, such as adequate biocompatibility, ability to improve therapeutic efficiency of incorporated drugs and to limit their adverse effects. Among a variety of reported nanomaterials for biomedical applications, metal and metal oxide-based nanoparticles offer unique physicochemical properties allowing their use in combination with conventional antimicrobials and as magnetic field-controlled drug delivery nanocarriers. An ever-growing number of studies demonstrate that by combining magnetic nanoparticles with membrane-active, natural human cathelicidin-derived LL-37 peptide, and its synthetic mimics such as ceragenins, innovative nanoagents might be developed. Between others, they demonstrate high clinical potential as antimicrobial, anti-cancer, immunomodulatory and regenerative agents. Due to continuous research, knowledge on pleiotropic character of natural antibacterial peptides and their mimics is growing, and it is justifying to stay that the therapeutic potential of nanosystems containing membrane active compounds has not been exhausted yet.
- Open Access
- 6 November 2019
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 26 (5) , 459-468
Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronary interventions
Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (pPCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. Results: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in in-hospital but not in 30-day or 1-year mortality rates between 2005 and 2011 results were similar in men and women. Conclusions: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy. Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (pPCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. Results: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in in-hospital but not in 30-day or 1-year mortality rates between 2005 and 2011 results were similar in men and women. Conclusions: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy.
- 6 November 2019
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 26 (5) , 459-468
Open AccessSurvival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronary interventions
Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (pPCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. Results: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in in-hospital but not in 30-day or 1-year mortality rates between 2005 and 2011 results were similar in men and women. Conclusions: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy. Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (pPCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. Results: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in in-hospital but not in 30-day or 1-year mortality rates between 2005 and 2011 results were similar in men and women. Conclusions: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy.
- Open Access
- 27 June 2019
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 26 (3) , 296-297
Coronary artery fistula and premature coronary atherosclerosis
- 27 June 2019
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 26 (3) , 296-297
Open AccessCoronary artery fistula and premature coronary atherosclerosis
- 1 May 2019
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 30 (3) , 171-176
Long-term outcomes in men and women with ST-segment elevation myocardial infarction and incomplete reperfusion after a primary percutaneous coronary intervention
The failure of reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI) is more frequent than considered previously. To evaluate sex-related differences in long-term outcomes in patients with STEMI and incomplete infarct-related artery reperfusion after a primary percutaneous coronary intervention. Of consecutive 42 752 patients with STEMI hospitalized between 2009 and 2011 in Poland, we analyzed a group of 766 (35%) women and 1453 (65%) men with less than thrombolysis in myocardial infarction (TIMI) flow grade 3 following a primary percutaneous coronary intervention. In the 2-year follow-up, the mortality rate among women was significantly higher compared with men: 39.8 versus 30.9% (P=0.0009) in the TIMI 0 or 1 group, and 31.6 versus 20% (P<0.0001) in the TIMI 2 group. In women, the risk of rehospitalization because of heart failure was significantly higher irrespective of the final TIMI flow grade. In the multivariate analysis, female sex did not influence both in-hospital (odds ratio: 1.09; 95% confidence interval: 0.82–1.44; P=0.54) and long-term (hazard ratio: 1.14; 95% confidence interval: 0.97–1.34; P=0.11) mortality. Peripheral artery disease, anterior myocardial infarction, and previous stroke were associated with increased mortality only in men. Postprocedural TIMI flow grade 2 (vs. TIMI grade 0 or 1) was the strongest factor impacting mortality irrespective of sex. Women with STEMI and postprocedural suboptimal epicardial blood flow have higher mortality than men and are at high risk of developing heart failure, with frequent in-patient visits. However, these differences may be attributed to the advanced age and worse clinical presentation of women compared with men.
- 1 May 2019
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 30 (3) , 171-176
Long-term outcomes in men and women with ST-segment elevation myocardial infarction and incomplete reperfusion after a primary percutaneous coronary intervention
The failure of reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI) is more frequent than considered previously. To evaluate sex-related differences in long-term outcomes in patients with STEMI and incomplete infarct-related artery reperfusion after a primary percutaneous coronary intervention. Of consecutive 42 752 patients with STEMI hospitalized between 2009 and 2011 in Poland, we analyzed a group of 766 (35%) women and 1453 (65%) men with less than thrombolysis in myocardial infarction (TIMI) flow grade 3 following a primary percutaneous coronary intervention. In the 2-year follow-up, the mortality rate among women was significantly higher compared with men: 39.8 versus 30.9% (P=0.0009) in the TIMI 0 or 1 group, and 31.6 versus 20% (P<0.0001) in the TIMI 2 group. In women, the risk of rehospitalization because of heart failure was significantly higher irrespective of the final TIMI flow grade. In the multivariate analysis, female sex did not influence both in-hospital (odds ratio: 1.09; 95% confidence interval: 0.82–1.44; P=0.54) and long-term (hazard ratio: 1.14; 95% confidence interval: 0.97–1.34; P=0.11) mortality. Peripheral artery disease, anterior myocardial infarction, and previous stroke were associated with increased mortality only in men. Postprocedural TIMI flow grade 2 (vs. TIMI grade 0 or 1) was the strongest factor impacting mortality irrespective of sex. Women with STEMI and postprocedural suboptimal epicardial blood flow have higher mortality than men and are at high risk of developing heart failure, with frequent in-patient visits. However, these differences may be attributed to the advanced age and worse clinical presentation of women compared with men.